The QPPV Role Explained: Responsibilities, Liability and Residency

What is the QPPV actually responsible for?

Oversight of the pharmacovigilance system as a whole, not merely case processing. That includes having a full overview of the safety profile of every authorised product, maintaining the pharmacovigilance system master file, ensuring the system operates as described, acting as the single point of contact for the competent authorities on a continuous basis, and having sufficient awareness to answer questions about any product without preparation. The role can be supported by a deputy and a team, and normally must be, but the accountability does not distribute. When an inspector wants to understand whether a pharmacovigilance system is real, the QPPV is where they start.

Why do inspectors test residency and authority first?

Because those two attributes are what make the role enforceable. Residency in the EU or EEA is a legal requirement, not a convenience: an authority that cannot reach the responsible person cannot regulate the system. Authority is subtler and more often deficient. A QPPV who cannot commission an audit, cannot require a change to a procedure, cannot see safety data from an affiliate without permission, or reports to someone whose incentives run the other way, holds the title without the function. Inspectors probe this with disarmingly simple questions: what did you change last quarter, and what happened when you disagreed with commercial.

How does the role fail in practice?

Almost always as a paper appointment. A senior person is named because the regulation requires a name, without the time to perform the role or the standing to act on it. The tell-tale signs are consistent: a pharmacovigilance system master file that is out of date, no documented evidence of the QPPV reviewing signal detection output, safety data exchange agreements the QPPV has never read, and an escalation route that has never been used. Outsourcing compounds this when it is treated as delegation of accountability rather than of activity. Duties can be contracted out; responsibility cannot.

Frequently asked questions

Can the QPPV be based outside the EU?

No. EU legislation requires the QPPV to reside and operate in the Union or the EEA. Where a company's safety operations sit elsewhere, the QPPV role still has to be genuinely performed from within the EU or EEA, not nominally located there.

Can a consultancy provide our QPPV?

Yes, and for smaller marketing authorisation holders this is common and legitimate, provided the individual is given real access, real authority and enough contracted time to do the job. What cannot be outsourced is the marketing authorisation holder's own responsibility for the system.

Does every marketing authorisation holder need a QPPV?

Every holder of a marketing authorisation for a medicinal product in the EU must have a pharmacovigilance system with a permanently available QPPV. The scale of the supporting team varies with portfolio size and risk; the requirement for the role does not.

Sources

1. Good pharmacovigilance practices (GVP) Module I — Pharmacovigilance systems and their quality systems, European Medicines Agency. ema.europa.eu
2. Regulation (EC) No 726/2004, European Union. eur-lex.europa.eu

Pending scientific review. This briefing summarises published regulatory guidance and has not yet been signed off by a named subject-matter expert. Verify against the primary sources below before relying on it.

Need a QPPV who can actually act?

We provide QPPV and deputy QPPV cover with the authority and availability the role requires, and we build the systems behind it.

Explore Pharmacovigilance ➔